These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 17026788)

  • 21. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis.
    Berry SR; Cosby R; Asmis T; Chan K; Hammad N; Krzyzanowska MK;
    Ann Oncol; 2015 Mar; 26(3):477-85. PubMed ID: 25057174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of a drug holiday: even patients with cancer need a vacation.
    Chu E
    Clin Colorectal Cancer; 2006 Sep; 6(3):182. PubMed ID: 17026785
    [No Abstract]   [Full Text] [Related]  

  • 23. Sound footing or slippery slope? The value of secondary analyses of randomized trials.
    Sargent D; Grothey A
    J Clin Oncol; 2007 Aug; 25(22):3191-3. PubMed ID: 17664465
    [No Abstract]   [Full Text] [Related]  

  • 24. Biochemical modulation of fluoropyrimidines: the "GISCAD" studies. GISCAD (Italian Group for the Study of Digestive Tract Cancer).
    Labianca R; Pancera G; Barni S; Cascinu S; Comella G; Foa P; Martignoni G; Zaniboni A; Giaccon G; Luporini G
    Adv Exp Med Biol; 1993; 339():233-7. PubMed ID: 8178720
    [No Abstract]   [Full Text] [Related]  

  • 25. [Chemotherapy for elderly patients with colorectal cancer].
    Takiguchi N; Soda H; Tonooka T; Denda T
    Nihon Rinsho; 2014 Jan; 72(1):139-42. PubMed ID: 24597362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coadministration of 5% glucose solution and dexamethasone and oxaliplatin-related vascular pain grade: a case study.
    Okada Y; Kajiume S; Taniguchi T; Kimoto S; Ogawa Y; Kiba T
    Clin J Oncol Nurs; 2013 Oct; 17(5):554-5. PubMed ID: 24080056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highlights in metastatic colorectal cancer from the 2012 American Society Of Clinical Oncology Annual Meeting.
    Grothey A
    Clin Adv Hematol Oncol; 2012 Jul; 10(7 Suppl 9):1-24. PubMed ID: 22895157
    [No Abstract]   [Full Text] [Related]  

  • 28. Optimum chemotherapy for metastatic colorectal cancer.
    Bendell J
    Lancet; 2006 Dec; 368(9552):2039-41. PubMed ID: 17161715
    [No Abstract]   [Full Text] [Related]  

  • 29. Sequential versus combination therapy: where are we?
    Chu E
    Clin Colorectal Cancer; 2008 Sep; 7(5):295. PubMed ID: 18794060
    [No Abstract]   [Full Text] [Related]  

  • 30. Medical treatment of colorectal cancer in elderly (>70 years): GISCAD experience and future perspectives. Italian Group for the Study of Digestive Tract Cancer.
    Beretta GD; Ferrari VD; Barni S; Pancera G; Labianca R
    Tumori; 2002; 88(1 Suppl 1):S109-12. PubMed ID: 11989900
    [No Abstract]   [Full Text] [Related]  

  • 31. Highlights from: 39th Annual Meeting of the American Society of Clinical Oncology: Chicago, Illinois. May 31 to June 3, 2003.
    Clin Colorectal Cancer; 2003 Aug; 3(2):78-84. PubMed ID: 12952561
    [No Abstract]   [Full Text] [Related]  

  • 32. Can we individualize chemotherapy for colorectal cancer?
    Chan R; Kerr DJ
    Ann Oncol; 2004 Jul; 15(7):996-9. PubMed ID: 15205190
    [No Abstract]   [Full Text] [Related]  

  • 33. Expert consensus on maintenance treatment for metastatic colorectal cancer in China.
    Xu RH; Shen L; Li J; Xu JM; Bi F; Ba Y; Bai L; Shu YQ; Liu TS; Li YH; Bai CM; Yuan XL; Zhang J; Chen G; Zhou AP; Yuan Y; Wang XJ; Qian XP; Deng YH
    Chin J Cancer; 2016 Jan; 35():13. PubMed ID: 26769299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial.
    Król A; Ferrer L; Pignon JP; Proust-Lima C; Ducreux M; Bouché O; Michiels S; Rondeau V
    Biometrics; 2016 Sep; 72(3):907-16. PubMed ID: 26890381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying disease progression in patients with metastatic colorectal cancer: when to initiate third-line therapy.
    Bekaii-Saab TS
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):2-7. PubMed ID: 33843904
    [No Abstract]   [Full Text] [Related]  

  • 36. Refining the use and sequencing of third-line therapy in patients with metastatic colorectal cancer.
    Grothey A
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):7-14. PubMed ID: 33843905
    [No Abstract]   [Full Text] [Related]  

  • 37. The importance of exposing patients with metastatic colorectal cancer to all treatment options.
    Loupakis F
    Clin Adv Hematol Oncol; 2021 Jan; 19 Suppl 3(1):3-5. PubMed ID: 33843899
    [No Abstract]   [Full Text] [Related]  

  • 38. Proactive transitioning to third-line treatment in metastatic colorectal cancer.
    Bekaii-Saab TS
    Clin Adv Hematol Oncol; 2021 Jan; 19 Suppl 3(1):5-7. PubMed ID: 33843900
    [No Abstract]   [Full Text] [Related]  

  • 39. Front-Line Treatment of Metastatic Colorectal Cancer.
    Sama AR; Cohen SJ
    J Oncol Pract; 2016 Dec; 12(12):1231-1233. PubMed ID: 27943685
    [No Abstract]   [Full Text] [Related]  

  • 40. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study.
    Moscetti L; Nelli F; Fabbri MA; Sperduti I; Alesini D; Cortesi E; Gemma D; Gamucci T; Grande R; Pavese I; Franco D; Ruggeri EM
    Invest New Drugs; 2013 Aug; 31(4):1035-43. PubMed ID: 23417697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.